Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Celgene Corporation.
Release Date: August 30, 2018
Expiration Date: August 30, 2019
Media: Internet - based
This activity, Oncology Briefings™: Treating Advanced NSCLC Without Actionable Mutations, developed in Physicians’ Education Resource, LLC, (PER®) established Oncology Briefings™ legacy format, is an online interactive monograph that provides treatment strategies for patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations. This presentation features a national thought leader, Thomas E. Stinchcombe, MD, who provides key insights.
Instructions for This Activity and Receiving Credit
This activity is directed toward oncology healthcare professionals who treat patients with lung cancer, including medical oncologists, radiology oncologists, and surgical oncologists. Fellows, nurses, nurse practitioners, pulmonologists, physician assistants, and other healthcare professionals involved in the management of patients with lung cancers are also invited to participate.
Upon completion of this activity, you should be better prepared to:
Thomas E. Stinchcombe, MD
Professor of Medicine
Duke Cancer Institute
Disclosure: Grant/Research Support: AstraZeneca, Genentech/Roche, Takeda (institution); Consultant: Takeda, Novartis, Genentech/Roche, AstraZeneca
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty member, and do not reflect those of PER® or the company that provided commercial support for this activity.
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Multiple Myeloma
Feb 28, 2019
Feb 28, 2019
Feb 28, 2019
23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
February 28, 2019 - March 3, 2019